12:00 AM
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TL-118: Phase II started

Tiltan began an open-label, Israeli Phase II trial to compare oral TL-118 once daily plus gemcitabine vs. gemcitabine alone in 80...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >